Background {#sec1}
==========

Atrial flutter (AFL) is a macroreentrant tachycardia propagating clockwise or counterclockwise through the cavotricuspid isthmus (CTI) and can cause stroke, heart failure, and significant subjective symptoms. To date, catheter ablation remains the recommended therapy for a wide variety of arrhythmias \[[@B1]\]. Ablation, whether radiofrequency ablation (RF) or cryoablation(CRYO) the two widespread ablation procedures, is the curative treatment for AFL \[[@B2],[@B3]\].

Several studies have indicated an increase in myocardial injury biomarkers such as troponin T (TnT), \[[@B4],[@B5]\] troponinI (TnI), \[[@B6]\] creatine kinase (CK), \[[@B9],[@B10]\] and or its creatine kinase MB(CK-MB) after RF \[[@B10],[@B11]\]. RF ablation can potentially cause serious complications \[[@B12],[@B13]\]. CRYO of CTI, an alternative therapeutic approach, has been shown to reduce pain during the ablation procedure and decrease the risk of damage to the right coronary artery and the conduction system \[[@B14]\].

Our aim was to study and comparatively evaluate changes in levels of necrotic biomarkers, and the resulting pain perception during energy application.

Methods {#sec2}
=======

Data sources and search strategy {#sec2-1}
--------------------------------

The present meta-analysis was performed in accordance with the Preferred Reporting Items for Systematic Reviews and Meta-analyses (PRISMA) guidelines \[[@B18],[@B19]\]. PubMed, Embase, Cochrane Library, and CBM databases were searched using the following keywords: Radiofrequency, Cryoablation, Atrial flutter, myocardial injury, and pain perception. No restrictions were imposed on language or date of publication. The final search was run on 1 October 2018. Additional searches were performed based on retrieved articles aiming to identify studies missed by prior searches.

Study selection {#sec2-2}
---------------

All randomized controlled trials (RCTs) and quasi RCTs with a target population of AFL patients were included in the present study. The study selection diagram is shown in [Figure 1](#F1){ref-type="fig"}. Randomized, crossover studies were also considered for inclusion.

![Selection process of studies included in the meta-analysis](bsr-39-bsr20182251-g1){#F1}

RCTs with different outcomes than the ones of interest, studies lacking a comparable control or placebo, animal studies, reviews, meeting abstracts, and case-only studies were excluded.

End point definition {#sec2-3}
--------------------

End points of the present study are as follows: 'CK levels (4--6 h and 12--24 h after ablation) (U/l)', 'CK-MB levels (4--6 h and 12--24 h after ablation) (U/l)', 'TnI levels (6 h post-ablation) (µg/l)', 'TnT levels (4--6 h after ablation and next morning) (µg/l)', and 'pain perception'.

Data extraction and quality assessment {#sec2-4}
--------------------------------------

Data were extracted by two independent reviewers using a standardized data-extraction protocol and disagreements were resolved by consensus. Extracted data included: (i) study characteristics (title, first author name, year of publication, design, and duration); (ii) participant characteristics (age, sex, body mass index, presence of other chronic diseases such as hypertension, diabetes); (iii) outcome (CK levels, CK-MB levels, TnI levels, TnT levels, and pain perception). The quality of each RCT was evaluated using the Cochrane risk of bias instrument which, primarily assesses randomization and allocation concealment, the blinding process of individuals involved in the trial, the completeness of follow-up, and the outcome. Each study outcome was classified as 'low risk of bias', 'unclear', or 'high risk of bias'.

Data synthesis and statistical analysis {#sec2-5}
---------------------------------------

Statistical analysis was conducted by the Cochrane Review Manager (RevMan version 5.3). Continuous and dichotomous outcomes were analyzed using respectively mean differences (MDs) and pooled odds ratio (OR) to combine different tests and measurement scales within each domain. The overall effect estimates were calculated using inverse variance weighted fixed-effects analysis with a 95% confidence interval (CI). Standard deviations (SDs) were calculated using the following formula: SD = square root \[(SD pretreatment)2 + (SD post-treatment)2 -- (2R × SD pre-treatment × SD post-treatment)\], assuming a correlation coefficient of (R) = 0.5.

Based on the Cochran Q statistic, heterogeneity among studies was identified using a standard χ^2^ test and a *P*-value (two-sided) \[[@B20]\]. *I^2^* index, as the percentage of variation across studies, was used to assess heterogeneity with *I^2^* values of 25, 50 or 75% representing low, moderate, or high heterogeneity, respectively \[[@B21]\]. The fixed-effect model was used for analysis when *I^2^* \< 50% and the random-effect model when *I^2^* ≥ 50%. Subgroup analysis or sensitivity analysis methods were used to explore the sources of heterogeneity and to explain possible causes. We planned to construct a funnel plot for risk of publication bias evaluation given that the number of included studies was greater than 10.

Results {#sec3}
=======

Study selection and characteristics {#sec3-1}
-----------------------------------

Of the initial 1160 studies identified by our primary search strategy, 58 duplicates were identified and removed. Further 949 studies were excluded after review of their titles and abstracts. Among the remaining 153 studies qualified for full-text review, 145 were excluded for the reason that 55 were published in the form of meta-analysis, abstracts, short communications or brief reports, 38 were animal studies, 24 were duplicated studies, and 28 did not report the outcomes of interest. Finally, six RCTs and two non-RCTs with a total sample size of 644 patients and an average follow-up period of 1day to 9 months were included in the present study ([Figure 1](#F1){ref-type="fig"} and [Tables 1](#T1){ref-type="table"} and [2](#T2){ref-type="table"}). The risk of bias among the included trials was generally low.

###### Characteristics of eight clinical trials included in the meta-analysis

  Study, year                         Study design                      Follow-up time   Outcome
  ----------------------------------- --------------------------------- ---------------- ---------------------------------
  Hernández-Romero, 2013 \[[@B22]\]   Non-random, Unblind, Control      2 months         CK, CK-MB, TnI
  Oswald, 2007 \[[@B23]\]             Non-random, Unblind, Control      1 day            CK, CK-MB, TnT
  Saygi, 2016 \[[@B24]\]              Single-blinded, Random, Control   1 day            TnI
  Thornton, 2008 \[[@B16]\]           Random, Control                   9 months         CK, CK-MB, TnT, Pain perception
  Bastani, 2012 \[[@B14]\]            Single-blinded, Random, Control   6 months         Pain perception
  Timmermans, 2003 \[[@B15]\]         Random, Control                   6 months         Pain perception
  Malmborg, 2009 \[[@B28]\]           Random, Control                   6 months         Pain perception
  Kuniss, 2009 \[[@B29]\]             Random, Control                   3 months         Pain perception

###### Characteristics of patients from eight clinical trials included in the meta-analysis

  Study, year                         Subjects (male)   Age (years)   Sex (male, %)   Hypertension (%)   Diabetes (%)   Body mass index (%)                                      
  ----------------------------------- ----------------- ------------- --------------- ------------------ -------------- --------------------- ------ ------ ------ ------ ------ ------
  Hernández-Romero, 2013 \[[@B22]\]   12                10            61.2            65.1               75             75                    41.7   60     33.3   20     27.7   29.5
  Oswald, 2007 \[[@B23]\]             10                9             62              68                 80             100                   37.5   37.5   37.5   37.5   30     27
  Saygi, 2016 \[[@B24]\]              78                75            65              65                 91             92                    39     25     5      8      100    99
  Thornton, 2008 \[[@B16]\]           32                30            55              56                 84             93                    NR     NR     NR     NR     NR     NR
  Bastani, 2012 \[[@B14]\]            78                75            65              65                 91             79                    39.7   22.7   5.1    8      NR     NR
  Timmermans, 2003 \[[@B15]\]         7                 7             55              555                85.7           71.4                  14.3   28.6   NR     NR     NR     NR
  Malmborg, 2009 \[[@B28]\]           20                20            57              60                 85             90                    25     25     NR     NR     27.2   24.7
  Kuniss, 2009 \[[@B29]\]             90                91            65              65                 77.8           83.5                  47.8   51.6   10     18.7   NR     NR

NR: Not described.

Detailed summary of involved studies and corresponding outcomes is as follows: four studies with CK levels as an outcome (three studies with a total of 22 patients in the CRYO group and 19 patients in the RF group and a timeline of 4--6 h post-ablation \[[@B16],[@B22],[@B23]\]; three studies with a total of 22 patients in the CRYO group and 19 patients in the RF group and a timeframe of 12--24 h \[[@B22],[@B23],[@B25]\]); three studies with CK-MB levels as an outcome of interest (three studies with a 4--6 h timeline, 22 patients in the CRYO group and 19 in RF group \[[@B16],[@B22],[@B23]\]; two studies with a 12--24 h timeline, 44 patients in the CRYO group and 40 in RF group \[[@B16],[@B22]\]); two studies with TnI levels as an outcome (a time period of 6 h, a total of 90 patients enrolled in the CRYO group and 85 in the RF group \[[@B22],[@B24]\]); two studies with TnT levels as an outcome of interest (a timeframe of 4--6 h and the next morning after ablation, 42 patients in the CRYO group and 39 patients in the RF group \[[@B16],[@B23]\]) and finally, five studies with pain perception as outcome (CRYO, 227 patients; RF, 223 patients \[[@B14],[@B28],[@B29]\]).

Risk of bias in included studies and quality of evidence {#sec3-2}
--------------------------------------------------------

The overall quality of the included studies, evaluated by the Cochrane risk of biases tool, was moderated and is shown in [Figures 2](#F2){ref-type="fig"} and [3](#F3){ref-type="fig"}. All studies were considered to have a low risk of bias in selective reporting according to the review of their protocols. All trials were regarded as having an unclear risk in other bias domain.

![Risk of bias graph](bsr-39-bsr20182251-g2){#F2}

![Risk of bias summary](bsr-39-bsr20182251-g3){#F3}

Efficacy outcomes {#sec3-3}
-----------------

### Serum CK levels {#sec3-3-1}

Substantial heterogeneity in serum CK levels was observed among studies with a significant increase seen in the CRYO group compared with the RF groups (MD = 179.54, 95%CI (95% confidence interval) (10.09, 348.98), *P*=0.04) minutes after the procedure ([Figure 4](#F4){ref-type="fig"}A). Although not statistically significant, an increase in CK levels could be seen at 4--6 h (MD = 62.74, 95%CI (−101.92, 227.40), *P*=0.46) ([Figure 4](#F4){ref-type="fig"}B) and 12--24 h (MD = 30.73, 95%CI (−55.89, 117.35), *P*=0.49) ([Figure 4](#F4){ref-type="fig"}C) after ablation in the CRYO group.

![Forest plot for changes in serum CK levels](bsr-39-bsr20182251-g4){#F4}

![Forest plot for changes in serum CK-MB levels](bsr-39-bsr20182251-g5){#F5}

![Forest plot for changes of serum TnI, TnT levels](bsr-39-bsr20182251-g6){#F6}

![Forest plot for changes in pain perception](bsr-39-bsr20182251-g7){#F7}

### Serum CK-MB levels {#sec3-3-2}

Substantial heterogeneity in serum CK-MB levels was observed among studies 4--6 hours after ablation with a significant increase seen in the CRYO group compared with the RF group (MD = 10.08, 95%CI (3.14, 17.02), *P*=0.004\] ([Figure 5](#F5){ref-type="fig"}A). Additionally, a slight increase (MD = 17.32, 95%CI (−12.45, 47.10), *P*=0.25) ([Figure 5](#F5){ref-type="fig"}B) in CK-MB levels can be seen 12--24 h after ablation in the CRYO group.

### Serum TnI levels {#sec3-3-3}

The results indicated that CRYO treatment significantly elevated TnI levels (MD = 0.12, 95%CI (−0.02, 0.26), *P*=0.08) 6 h after ablation ([Figure 6](#F6){ref-type="fig"}A).

### Serum TnT levels {#sec3-3-4}

Substantial heterogeneity in serum TnT levels among studies was observed the next morning with a significant increase seen in the CRYO group as compared with RF group (MD = 0.19, 95%CI (0.07, 0.32), *P*=0.002\] ([Figure 6](#F6){ref-type="fig"}C). A slight increase in TnT levels was also observed 4--6 hours (MD = 0.30, 95%CI (−0.03, 0.63, *P*=0.08) ([Figure 6](#F6){ref-type="fig"}B) after ablation in the CRYO group.

### Pain perception {#sec3-3-5}

The results indicated that treatment with CRYO significantly reduced pain perception (OR = 0.05, 95%CI (0.00, 0.84), *P*=0.04) ([Figure 7](#F7){ref-type="fig"}).

Discussion {#sec4}
==========

In RF cases, the injury usually results in much larger lesions \[[@B30],[@B31]\] and seems to be associated with the site of ablation and the number of RF application \[[@B32]\]. Additionally, RF seems to favor the development of inflammatory infiltrates and fibrosis.

Ablation using cryothermal energy has several potential advantages including greater catheter stability due to better adherence to myocardial tissue, a lower risk of thrombus formation and systemic embolization, and a lower probability of myocardial perforation due to the preservation of tissue architecture \[[@B17],[@B25],[@B33]\].

This meta-analysis had several limitations. First, a susceptibility to bias due to smaller sample size and a limited number of clinical trials. Second, significant heterogeneity between studies could be observed. Additionally, biomarkers levels assessment started immediately after ablation.

There are also several concerns regarding clinical environment under which the cardiac necrosis biomarkers were used and then compared across different studies. In the work of Oswald et al. \[[@B23]\], patients with normal baseline values of cardiac biomarkers were included, while in the study of Thornton et al. \[[@B16]\] and Hernandez-Romero et al. \[[@B22]\], authors did not provide conditions under which patients were included in the study, as well as the basal level of their cardiac biomarkers. Therefore, it is difficult to assess and compare the effects of different studies since the clinical environment.

Therefore, the lack of baseline made it impossible to determine the confounding effect of baseline characteristics accurately. Third, there are risks of inaccurate conclusions due to potential heterogeneity among studies in terms of trial protocols, study populations, duration of ablation treatment. In summary, meta-analysis conclusions still need to be demonstrated by additional high-quality, large-sampled clinical studies.

Conclusions {#sec5}
===========

The present study indicates that CRYO significantly reduces pain perception and lowers discomfort during ablation. What was more, CRYO exhibited a higher occurrence of myocardial injury in comparison with RF.
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